| scholarly article | Q13442814 |
| P50 | author | Barton Haynes | Q4865631 |
| Guido Ferrari | Q56481169 | ||
| Mattia Bonsignori | Q56808332 | ||
| Georgia D. Tomaras | Q63663866 | ||
| M Anthony Moody | Q73297881 | ||
| Hua-Xin Liao | Q88608388 | ||
| Laurent Verkoczy | Q88773002 | ||
| Munir Alam | Q89520930 | ||
| P2093 | author name string | Feng Gao | |
| Garnett Kelsoe | |||
| P2860 | cites work | Design and pre-clinical evaluation of a universal HIV-1 vaccine | Q21092234 |
| Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | Q24635002 | ||
| HIV‐1 neutralizing antibodies: understanding nature's pathways | Q27000480 | ||
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | Q27675879 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans | Q27678062 | ||
| Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 | Q27678306 | ||
| Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 | Q27678312 | ||
| Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer | Q27680496 | ||
| Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer | Q27680497 | ||
| The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies | Q27680688 | ||
| A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies | Q28299280 | ||
| H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination | Q28743596 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Predominant autoantibody production by early human B cell precursors | Q29619656 | ||
| Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine | Q30578618 | ||
| A method for identification of HIV gp140 binding memory B cells in human blood | Q33394829 | ||
| Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance | Q33591736 | ||
| Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection | Q33702217 | ||
| Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys | Q33712291 | ||
| Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys | Q33712578 | ||
| Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates | Q33742529 | ||
| Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution | Q33778466 | ||
| Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination | Q33977866 | ||
| B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study | Q34273373 | ||
| Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 | Q34298408 | ||
| Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies | Q34324992 | ||
| Immune clearance of highly pathogenic SIV infection | Q34370314 | ||
| Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection | Q34402934 | ||
| Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. | Q34522657 | ||
| Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs | Q34539819 | ||
| N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function | Q34594978 | ||
| In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth | Q34937404 | ||
| Is developing an HIV-1 vaccine possible? | Q35043547 | ||
| The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection | Q35076717 | ||
| Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies | Q35116581 | ||
| Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls | Q35336374 | ||
| Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors | Q35382871 | ||
| Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development | Q36041356 | ||
| Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family | Q36363231 | ||
| Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape | Q36388754 | ||
| Antibody polyspecificity and neutralization of HIV-1: a hypothesis | Q36487151 | ||
| Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. | Q36489415 | ||
| Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens | Q36638450 | ||
| Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses | Q36693991 | ||
| Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. | Q36895518 | ||
| Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees | Q36978671 | ||
| Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
| Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer | Q37049334 | ||
| Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10 | Q37049675 | ||
| Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein | Q37123584 | ||
| Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10 | Q37171251 | ||
| Cytomegalovirus Vectors Violate CD8 + T Cell Epitope Recognition Paradigms | Q37278451 | ||
| Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. | Q37318213 | ||
| T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces | Q37333743 | ||
| Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys | Q37355237 | ||
| Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.). | Q37370393 | ||
| Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens | Q37456354 | ||
| Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. | Q37625296 | ||
| An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. | Q37680009 | ||
| Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity | Q37714023 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| HIV-1 hides an Achilles' heel in virion lipids | Q42220533 | ||
| HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages | Q42270590 | ||
| Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses | Q42278743 | ||
| Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines | Q42279030 | ||
| Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions | Q42561401 | ||
| Role of antigen receptor affinity in T cell-independent antibody responses in vivo | Q43918933 | ||
| Progress in HIV-1 vaccine development | Q56600657 | ||
| Role of BCR affinity in T cell dependent antibody responses in vivo | Q74139589 | ||
| Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers | Q77573886 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 3-10; quiz 11 | |
| P577 | publication date | 2014-06-26 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
| P1476 | title | Progress in HIV-1 vaccine development | |
| P478 | volume | 134 |
| Q36337888 | Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model. |
| Q40748041 | An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques |
| Q35641369 | Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency |
| Q36684710 | CXCL13 is a plasma biomarker of germinal center activity |
| Q38753943 | Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. |
| Q35651494 | Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop |
| Q40452508 | Comparison of the patterns of antibody recall responses to HIV-1 gp120 and hepatitis B surface antigen in immunized mice. |
| Q30397595 | Current views on the potential for development of a HIV vaccine |
| Q40639803 | Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique |
| Q92740226 | Deconvolving mutational patterns of poliovirus outbreaks reveals its intrinsic fitness landscape |
| Q40047250 | Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies |
| Q38405470 | Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region. |
| Q35913910 | Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL |
| Q39454581 | Germinal center enhancement by extended antigen availability |
| Q47555844 | HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis |
| Q33753950 | HIV-Enhancing and HIV-Inhibiting Properties of Cationic Peptides and Proteins |
| Q39108735 | Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies |
| Q37045832 | Human Immunodeficiency Virus (HIV). |
| Q40942917 | Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health |
| Q30234773 | Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem |
| Q39108796 | Identification and specificity of broadly neutralizing antibodies against HIV |
| Q39108760 | Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. |
| Q92210244 | Impact of HIV-1 Diversity on Its Sensitivity to Neutralization |
| Q36053149 | Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity |
| Q36246646 | Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants |
| Q59358562 | Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection |
| Q37634061 | Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies |
| Q35855579 | Oral Delivery of a Novel Recombinant Streptococcus mitis Vector Elicits Robust Vaccine Antigen-Specific Oral Mucosal and Systemic Antibody Responses and T Cell Tolerance |
| Q33804531 | Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge |
| Q39108740 | Polyvalent vaccine approaches to combat HIV-1 diversity |
| Q40960044 | Tetraspanins displayed in retrovirus-derived virus-like particles and their immunogenicity. |
| Q39108730 | Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem |
| Q27000032 | The Role of Cationic Polypeptides in Modulating HIV-1 Infection of the Cervicovaginal Mucosa |
| Q27025177 | Virological features associated with the development of broadly neutralizing antibodies to HIV-1 |
Search more.